The ARRIBA concept: Adequate resorption of ribavirin

Clara T M M De Kanter; Ludi Koning; Floor A C Berden; Jan Christian Wasmuth; Karin J T Grintjes-Huisman; Brigitta Becker; Angela P H Colbers; Monique M B Roukens; Jürgen K. Rockstroh; Joost P H Drenth; Robert J. De Knegt; Anton S M Dofferhoff; David M. Burger

doi:10.3851/IMP2935

The ARRIBA concept: Adequate resorption of ribavirin

Clara T M M De Kanter^*, Ludi Koning, Floor A C Berden, Jan Christian Wasmuth, Karin J T Grintjes-Huisman, Brigitta Becker, Angela P H Colbers, Monique M B Roukens, Jürgen K. Rockstroh, Joost P H Drenth, Robert J. De Knegt, Anton S M Dofferhoff, David M. Burger

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Background: Adequate ribavirin exposure is essential for optimal sustained virological response (SVR) rates in chronic HCV treatment. It has been proposed that the area under the concentration-time curve up to 4 h after intake of ribavirin (AUC0-4 h) of the first weight-based ribavirin dose should be ≥1.755 mg•h/l to guarantee the highest chance of SVR. Our ARRIBA concept comprises a test dose of ribavirin to select the optimal starting dose to achieve adequate exposure. This study aims to evaluate whether adequate exposure can be achieved after dose advice based on the AUC0-4 h of a single weight-based ribavirin test dose. Methods: (Formerly) HCV-infected subjects received a single weight-based ribavirin test dose (

Original language	English
Pages (from-to)	515-520
Number of pages	6
Journal	Antiviral Therapy
Volume	20
Issue number	5
DOIs	https://doi.org/10.3851/IMP2935
Publication status	Published - 2015
Externally published	Yes

Access to Document

10.3851/IMP2935

Cite this

@article{4888d72d9b27474a8e06d9e0390ebc81,

title = "The ARRIBA concept: Adequate resorption of ribavirin",

abstract = "Background: Adequate ribavirin exposure is essential for optimal sustained virological response (SVR) rates in chronic HCV treatment. It has been proposed that the area under the concentration-time curve up to 4 h after intake of ribavirin (AUC0-4 h) of the first weight-based ribavirin dose should be ≥1.755 mg•h/l to guarantee the highest chance of SVR. Our ARRIBA concept comprises a test dose of ribavirin to select the optimal starting dose to achieve adequate exposure. This study aims to evaluate whether adequate exposure can be achieved after dose advice based on the AUC0-4 h of a single weight-based ribavirin test dose. Methods: (Formerly) HCV-infected subjects received a single weight-based ribavirin test dose (",

author = "{De Kanter}, {Clara T M M} and Ludi Koning and Berden, {Floor A C} and Wasmuth, {Jan Christian} and Grintjes-Huisman, {Karin J T} and Brigitta Becker and Colbers, {Angela P H} and Roukens, {Monique M B} and Rockstroh, {J{\"u}rgen K.} and Drenth, {Joost P H} and {De Knegt}, {Robert J.} and Dofferhoff, {Anton S M} and Burger, {David M.}",

year = "2015",

doi = "10.3851/IMP2935",

language = "English",

volume = "20",

pages = "515--520",

journal = "Antiviral Therapy",

issn = "1359-6535",

publisher = "Sage Publications",

number = "5",

}

TY - JOUR

T1 - The ARRIBA concept

T2 - Adequate resorption of ribavirin

AU - De Kanter, Clara T M M

AU - Koning, Ludi

AU - Berden, Floor A C

AU - Wasmuth, Jan Christian

AU - Grintjes-Huisman, Karin J T

AU - Becker, Brigitta

AU - Colbers, Angela P H

AU - Roukens, Monique M B

AU - Rockstroh, Jürgen K.

AU - Drenth, Joost P H

AU - De Knegt, Robert J.

AU - Dofferhoff, Anton S M

AU - Burger, David M.

PY - 2015

Y1 - 2015

N2 - Background: Adequate ribavirin exposure is essential for optimal sustained virological response (SVR) rates in chronic HCV treatment. It has been proposed that the area under the concentration-time curve up to 4 h after intake of ribavirin (AUC0-4 h) of the first weight-based ribavirin dose should be ≥1.755 mg•h/l to guarantee the highest chance of SVR. Our ARRIBA concept comprises a test dose of ribavirin to select the optimal starting dose to achieve adequate exposure. This study aims to evaluate whether adequate exposure can be achieved after dose advice based on the AUC0-4 h of a single weight-based ribavirin test dose. Methods: (Formerly) HCV-infected subjects received a single weight-based ribavirin test dose (

AB - Background: Adequate ribavirin exposure is essential for optimal sustained virological response (SVR) rates in chronic HCV treatment. It has been proposed that the area under the concentration-time curve up to 4 h after intake of ribavirin (AUC0-4 h) of the first weight-based ribavirin dose should be ≥1.755 mg•h/l to guarantee the highest chance of SVR. Our ARRIBA concept comprises a test dose of ribavirin to select the optimal starting dose to achieve adequate exposure. This study aims to evaluate whether adequate exposure can be achieved after dose advice based on the AUC0-4 h of a single weight-based ribavirin test dose. Methods: (Formerly) HCV-infected subjects received a single weight-based ribavirin test dose (

UR - http://www.scopus.com/inward/record.url?scp=84947224895&partnerID=8YFLogxK

U2 - 10.3851/IMP2935

DO - 10.3851/IMP2935

M3 - Article

C2 - 25599333

AN - SCOPUS:84947224895

SN - 1359-6535

VL - 20

SP - 515

EP - 520

JO - Antiviral Therapy

JF - Antiviral Therapy

IS - 5

ER -

The ARRIBA concept: Adequate resorption of ribavirin

Abstract

Access to Document

Other files and links

Fingerprint

Cite this